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Abstract 
The liver is susceptible to chronic damage through exposure to a variety of toxins (e.g. 
alcohol) and viruses (e.g. hepatitis C).  Obesity, autoimmune diseases (e.g. autoimmune 
hepatitis) and a variety of genetic diseases (e.g. Wilson’s disease) also lead to chronic 
liver damage.  This damage results in scarring fibrogenesis, structural disruption and 
functional impairment of the organ.  Recent work suggests that there is cross-talk 
between the PXR and NF-κB pathways.   This cross talk may explain the observation that 
PXR activators inhibit liver fibrosis in in vitro and in vivo animal models of the disease.  
this reveiw will focus on the two transcription factors and their potential interaction. 
 
1.  The PXR 
The pregnane x receptor (NR1I2) – or PXR - is a nuclear receptor transcription 
factor that regulates the expression of a range of genes associated with endobiotic and 
xenobiotic clearance (Kliewer et al., 2002; Chang and Waxman, 2006).  PXR function is 
normally activated through contact with a range of ligands, including existing licensed 
drugs (e.g rifampicin) and endogenous compounds (steroids, bile acids) (Kliewer et al., 
2002; Chang and Waxman, 2006) (see Figure 1 and Table 1). 
 
2. Liver fibrosis and NF-κB 
Liver fibrosis occurs in response to chronic liver damage.  It is associated with an 
inflammatory reaction to tissue damage which stimulates hepatic stellate cell trans-
differentiation to myofibroblasts and/or existing liver myofibroblast proliferation 
(Iredale, 2007).  In a chronic liver damage setting, liver myofibroblasts secrete and 
promote the accumulation of scarring extracellular matrix (e.g. collagen type I) that 
ultimately distorts tissue structure, disrupts blood flow, leading to cirrhosis (Iredale, 
2007).  A number of reports have indicated that NF-κB plays a pivotal role in liver 
myofibroblast viability and fibrogenesis (Elsharkawy et al., 1999; Wright et al., 2001; 
Kweon et al., 2003; Oakley et al., 2005; Anan et al., 2006). 
The term NF-κB describes a transcription factor heterodimeric complex of Rel* 
factors that mediate the expression of genes associated with inflammation in response to 
a range of stimuli (Ali and Mann, 2004) (see Figure 1 and Table 1).  Critically, NF-κB is 
constitutively active in pro-fibrogenic liver myofibroblasts due to an excess of Rel factors 
via an epigenetic down-regulation of the inhibitory I-κB protein (Mann et al., 2007).  A 
major function of NF-κB in liver myofibroblasts is the inhibition of apoptosis 
(Elsharkawy et al., 1999; Wright et al., 2001; Oakley et al., 2005).  Accordingly, 
inhibition of NF-κB in vitro (Elsharkawy et al., 1999; Wright et al., 2001) and in vivo 
(Wright et al., 2001; Oakley et al., 2005) stimulates liver myofibroblast apoptosis and 
promotes fibrosis reversal. 
With respect to treatments for liver fibrosis, a potential concern with the use of 
inhibitors of NF-κB without their specific targeting to liver myofibroblasts could be the 
death of hepatocytes (and therefore an exacerbation of liver damage).  In vitro, 
hepatocytes readily undergo apoptosis when NF-κB is inhibited under pro-inflammatory 
and oxidising (NF-κB activating) conditions (Bradham et al., 1998; Hatano et al., 2001a), 
the likely environment in a chronic liver damage setting.  This response may also occur in 
vivo (Chang et al., 2006; Beraza et al., 2007 Geisler et al., 2007) although some data 
suggests it may be an in vitro phenomenon (Luedde et al., 2005). 
 
3. The PXR and liver fibrosis 
Recent work from this laboratory has shown that PXR ligand activators are anti-
fibrogenic in human liver myofibroblasts in vitro (Haughton et al., 2006) and in in vivo 
animal models of liver fibrosis (Marek et al., 2005).  Using mice with a disrupted PXR 
gene, the role of the PXR was unequivocally established (Marek et al., 2005).  The 
mechanism of action of the PXR was independent of any effects on liver damage (using 
carbon tetrachloride) and is likely associated with a novel function for the PXR in cells 
other than hepatocytes and its recognised function as a regulator of genes associated with 
endobiotic and xenobiotic clearance (Wright, 2006).  This is supported by recent work in 
other labs that has proposed that PXR activation inhibits the expression of genes 
regulated by inflammation in the gut such as IL-1β and iNOS (Zhou et al., 2006; Shah et 
al., 2007). 
 
 
4. The PXR inhibits NF-κB transcriptional function 
It is known that the nuclear receptor peroxisome proliferator activated receptor-γ 
(PPARγ) inhibits NF-κB (Su et al., 1999; Wang et al., 2007).  The effect of PXR 
activators on NF-κB transcriptional regulation was therefore investigated using a human 
monocytic U937 cell line stably transfected with a luciferase gene under control of NF-
κB response elements (Axon et al., in press).  Treating this cell line with the cytokine 
tumour necrosis factor α (TNFα) or bacterial lipopolysaccharide (LPS) induced 
expression of luciferase.  Co-treatment with PXR activators inhibited the expression of 
LPS-induced luciferase but not TNFα-induced luciferase activity.  These data suggest 
that the PXR may inhibit NF-κB function with respect to some NF-κB activation signals.  
Lack of effect on TNFα-activated NF-κB may have been associated with a stimulation of 
apoptosis by this cytokine in the U937 cell line. 
 
5. Conclusions 
 There is now evidence within the literature to suggest that the PXR nuclear 
receptor inhibits NF-κB and inhibits inflammation.  With regard to liver fibrosis however, 
there remain a number of questions.  These include whether NF-κB and the PXR interact 
within hepatocytes and/or liver myofibroblasts?  With respect to the latter, NF-κB 
inhibition is known to stimulate apoptosis, yet PXR activation in myofibroblasts inhibits 
proliferation and fibrogenicity but does not promote apoptosis (Haughton et al., 2006).  It 
is tempting to hypothesise that the PXR may interact selectively with specific Rel 
combinations or act on selected NF-κB response elements to bring about a selected 
inhibition of NF-κB function.  The precise mechanism(s) of interaction are yet to be 
determined. 
 
*Rel proteins were so named because of their sequence homology with the retroviral 
oncoprotein v-Rel (reticuloendotheliosis viral oncogene). 
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Figure Legends 
Figure 1.  Schematic diagram of PXR and NF-κB signalling.  TLR4, toll like receptor 
4 is the receptor for LPS (for review see Doyle and O’Neill, 2006). TNFR, TNFα 
receptor (for review see Wullaert et al., 2007).  There are sub-types for this receptor.  
TNFR1 is associated with interactions with soluble TNFα and hepatocyte apoptosis (Doi 
et al., 1999).  RXR, retinoid X receptor; ER6, response element for the human PXR 
(Lehmann et al., 1998); NF-κB RE, response element for transcriptionally functional Rel 
dimers; IKK, IκB kinase; I-κB, the functional inhibitor protein of NF-κB 
 
